News

The FDA approval for marketing of bromfenac ophthalmic solution 0.09% (Xibrom, ISTA Pharmaceuticals) gives the topical medication the distinction of being the first nonsteroidal anti-inflammatory drug (NSAID) in the United States indicated for twice-daily instillation in the management of ocular inflammation after cataract surgery.

Washington, DC &#8212 Circular lamellar keratomileusis (CLK) is a new surgical procedure that offers a potentially safer alternative to LASIK for the treatment of low myopia (up to -5 D), myopic presbyopia, and emmetropic presbyopes, said Gholam Peyman, MD, at the Innovators Session.

Washington, DC &#8212 Members of Ophthalmic Women Leaders (OWL) gathered Monday for an evening of networking at the American Society of Cataract and Refractive Surgery (ASCRS) meeting.

Washington, DC &#8212 Alcon Laboratories Inc. introduced the newest addition to its IOL family during a press conference Monday. The AcrySof ReSTOR apodized diffractive IOL recently received FDA approval for cataract surgery in patients with or without presbyopia.

Washington, DC &#8212 The AcrySof Natural SN60AT IOL (Alcon Laboratories) provides the same quality of vision as the conventional single-piece AcrySof IOL (Alcon Laboratories) under different degrees of contrast and different light conditions, reported Newton Kara-Jose Jr., MD, during a cataract symposium on phacoemulsification and IOLs at the American Society of Cataract and Refractive Surgery annual meeting.

Washington, DC &#8212 Good near and distance visual acuity may be achieved in mild-to-moderate hyperopia in patients using a bilateral treatment approach, reported Marguerite B. McDonald, MD, who spoke at a refractive symposium on hyperopia, conductive keratoplasty (CK, Refractec), and LASIK during the American Society of Cataract and Refractive Surgery annual meeting.

Washington, DC &#8212 Results of a prospective, randomized, double-masked, vehicle-controlled clinical trial demonstrate the efficacy and safety of nepafenac 0.1% ophthalmic suspension for reducing anterior segment inflammation and minimizing pain after cataract surgery, said Stephen S. Lane, MD.

Washington, DC &#8212 Significant wound burn occurs in about 1 in 1,000 cases of phacoemulsification, but its incidence is influenced by surgical technique, reported Randall J. Olson, MD.

Washington, DC &#8212 Circular lamellar keratomileusis (CLK) is a new surgical procedure that offers a potentially safer alternative to LASIK for the treatment of low myopia (up to -5 D), myopic presbyopia, and emmetropic presbyopes, said Gholam Peyman, MD, at the Innovators Session.

Washington, DC &#8212 Accruing experience with the AlphaCor synthetic keratoprosthesis has led to the identification of risk factors for complications along with the development of protective procedures that are enabling better results, said R. Doyle Stulting, MD.

Washington, DC &#8212 Conventional LASIK for moderate myopia generally reduces night-driving performance, but the frequency of that effect differs between laser platforms, said Steve C. Schallhorn, MD.

Washington, DC &#8212 The topic of healthcare continues to garner much debate on Capitol Hill. Former congressman and practicing physician Sen. Tom A. Coburn, MD (R-OK) kicked off the Government Relations General Session at the American Society of Cataract and Refractive Surgery meeting.

Washington, DC &#8212 phthalmologists discovered something "new" and something "old" Sunday evening during the "Innovations in Cataract and Refractive Surgery" symposium, sponsored by the Dulaney Foundation and supported by an educational grant from Alcon Laboratories.

Washington, DC &#8212 Attendees of the American Society of Cataract and Refractive Surgery meeting enjoyed a festive evening of Australian wines, hors d'oeuvres, and music at a Sunday evening reception sponsored by Norwood EyeCare, a subsidiary of Norwood Abbey Ltd. The Australian-based company has much to celebrate.

Washington, DC &#8212 Preliminary results from the ongoing FDA clinical trials of the Allegretto Wave wavefront-guided excimer laser (WaveLight Laser Technologie AG) demonstrate the safety and efficacy of this new platform, when compared with the approved wavefront-optimized platform, reported Steven Brint, MD, medical monitor for the FDA study, during a Sunday evening presentation at the American Society of Cataract and Refractive Surgery annual meeting.

Washington, DC &#8212 As refractive surgeons are revisiting surface ablation, the EpiLift System (Advanced Refractive Technologies/VisiJet) offers an advanced approach incorporating safe, simple, and precise mechanical epithelial separation.

Washington, DC &#8212 WaveLight Inc. and SurgiVision Consultants Inc. of Scottsdale, AZ, introduce an exclusive new service for users of the Allegretto Wave excimer laser system.

Washington, DC &#8212 Could laser vision correction be a safer alternative to IOL exchange in patients with ametropia after cataract surgery? That is the question that Irene C. Kuo, MD, and her colleagues tried to answer in a small study of patients who underwent LASIK or PRK to correct this problem.

Washington, DC &#8212 Conventional LASIK for moderate myopia generally reduces night-driving performance, but the frequency of that effect differs between laser platforms, said Steve C. Schallhorn, MD.

Washington, DC &#8212 Laser vision correction and refractive lens exchange (RLE) with a multifocal IOL may offer hope for hyperopic eyes with large amounts of astigmatism or residual astigmatism or eyes with presbyopia, according to Kevin L. Waltz, MD, who spoke about the results of retrospective chart review during a cataract/refractive symposium during the American Society of Cataract and Refractive Surgery annual meeting.

Washington, DC &#8212 Clear lens replacement is considered a good option for patients who are well-educated about the risk factors pertaining to retinal detachment, explained J. Pitzer Gills III, MD, who spoke during a cataract/refractive symposium on refractive lens exchange, bioptics, and intracorneal lenses during the American Society of Cataract and Refractive Surgery annual meeting.

Washington, DC &#8212 A good visual outcome is often achieved following primary IOL placement in pediatric eyes undergoing removal of traumatic cataract, said Richard Golub, MD.

Washington, DC &#8212 Growing the refractive surgery market relies on educating potential candidates about the benefits of the procedure and allaying irrational conclusions about risks, reported Shareef Mahdavi, MD.

Washington, DC &#8212 If capsule bag fixation is not possible, cataract surgeons may want to consider options for optic capture depending on the particular problems that present, according to Howard V. Gimbel, MD.

Washington, DC &#8212 With the recent acquisition of VISX and last month's FDA approval of its ReZoom multifocal refractive lens, Advanced Medical Optics (AMO) appears to be experiencing "some exciting times" in ophthalmology.

Washington, DC &#8212 An international panel of clinicians and visual science researchers concur that there is profound existing evidence and continually accumulating data supporting the use of blue light-filtering IOL technology.

Washington, DC &#8212 Bausch & Lomb announced that the U.S. Food and Drug Administration has approved the single-indication orphan drug Retisert (fluocinolone acetonide intravitreal implant), 0.59 mg, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Washington, DC &#8212 Initial results from a prospective, parallel group comparison trial slightly favor use of the femtosecond microkeratome (IntraLase) compared with two mechanical microkeratomes for performing wavefront-guided LASIK.However, they point to no benefits when performing the procedures using a staged approach that takes into account the potential for flap creation to affect higher order aberrations compared with standard immediate ablation, reported David Tanzer, MD, at the American Society of Cataract and Refractive Surgery meeting.